Qianhua Ou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Qianhua Ou has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
A. Li
Department of Clinical Medicine, Guangdong Medical University, Zhanjiang, China
2 shared publications- Herui Yao
Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Guangdong-Hong Kong Joint Laboratory for RNA Medicine, Department of Medical Oncology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China
2 shared publications - Yonghui Chen
Department of Medical Oncology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
2 shared publications - Aneesha Acharya
Division of Periodontology and Implant Dentistry, Faculty of Dentistry, The University of Hong Kong, Hong Kong SAR, China
1 shared publication - Anthony Chukwunonso Ogbuehi
Faculty of Physics, University of Münster, Wilhelm-Klemm-Straße 9, 48149 Münster, Germany
1 shared publication - Chu‐Long Xie
Department of Thoracic Surgery Sun Yat‐sen University Cancer Center Guangzhou China
1 shared publication
Latest Publications
- RetractedOpen Access
- 1 January 2021
- Published by Wiley in BioMed Research International
- Vol. 2021 (1)
[Retracted] Identification of the Potential Biomarkers Involved in the Human Oral Mucosal Wound Healing: A Bioinformatic Study
Objective. To identify the key genetic and epigenetic mechanisms involved in the wound healing process after injury of the oral mucosa. Materials and Methods. Gene expression profiling datasets pertaining to rapid wound healing of oral mucosa were identified using the Gene Expression Omnibus (GEO) database. Differential gene expression analysis was performed to identify differentially expressed genes (DEGs) during oral mucosal wound healing. Next, functional enrichment analysis was performed to identify the biological processes (BPs) and signaling pathways relevant to these DEGs. A protein‐protein interaction (PPI) network was constructed to identify hub DEGs. Interaction networks were constructed for both miRNA‐target DEGs and DEGs‐transcription factors. A DEGs‐chemical compound interaction network and a miRNA‐small molecular interaction network were also constructed. Results. DEGs were found significantly enriched in several signaling pathways including arachidonic acid metabolism, cell cycle, p53, and ECM‐receptor interaction. Hub genes, GABARAPL1, GABARAPL2, HDAC5, MAP1LC3A, AURKA, and PLK1, were identified via PPI network analysis. Two miRNAs, miR‐34a‐5p and miR‐335‐5p, were identified as pivotal players in the miRNA‐target DEGs network. Four transcription factors FOS, PLAU, BCL6, and RORA were found to play key roles in the TFs‐DEGs interaction network. Several chemical compounds including Valproic acid, Doxorubicin, Nickel, and tretinoin and small molecular drugs including atorvastatin, 17β‐estradiol, curcumin, and vitamin D3 were noted to influence oral mucosa regeneration by regulating the expression of healing‐associated DEGs/miRNAs. Conclusion. Genetic and epigenetic mechanisms and specific drugs were identified as significant molecular mechanisms and entities relevant to oral mucosal healing. These may be valuable potential targets for experimental research.
- 1 January 2021
- Published by Wiley in BioMed Research International
- Vol. 2021 (1)
RetractedOpen Access[Retracted] Identification of the Potential Biomarkers Involved in the Human Oral Mucosal Wound Healing: A Bioinformatic Study
Objective. To identify the key genetic and epigenetic mechanisms involved in the wound healing process after injury of the oral mucosa. Materials and Methods. Gene expression profiling datasets pertaining to rapid wound healing of oral mucosa were identified using the Gene Expression Omnibus (GEO) database. Differential gene expression analysis was performed to identify differentially expressed genes (DEGs) during oral mucosal wound healing. Next, functional enrichment analysis was performed to identify the biological processes (BPs) and signaling pathways relevant to these DEGs. A protein‐protein interaction (PPI) network was constructed to identify hub DEGs. Interaction networks were constructed for both miRNA‐target DEGs and DEGs‐transcription factors. A DEGs‐chemical compound interaction network and a miRNA‐small molecular interaction network were also constructed. Results. DEGs were found significantly enriched in several signaling pathways including arachidonic acid metabolism, cell cycle, p53, and ECM‐receptor interaction. Hub genes, GABARAPL1, GABARAPL2, HDAC5, MAP1LC3A, AURKA, and PLK1, were identified via PPI network analysis. Two miRNAs, miR‐34a‐5p and miR‐335‐5p, were identified as pivotal players in the miRNA‐target DEGs network. Four transcription factors FOS, PLAU, BCL6, and RORA were found to play key roles in the TFs‐DEGs interaction network. Several chemical compounds including Valproic acid, Doxorubicin, Nickel, and tretinoin and small molecular drugs including atorvastatin, 17β‐estradiol, curcumin, and vitamin D3 were noted to influence oral mucosa regeneration by regulating the expression of healing‐associated DEGs/miRNAs. Conclusion. Genetic and epigenetic mechanisms and specific drugs were identified as significant molecular mechanisms and entities relevant to oral mucosal healing. These may be valuable potential targets for experimental research.
- 15 December 2019
- Published by Elsevier in Annals of Oncology
- Vol. 30 (Supplement) , xi51-xi52
Association of MUC16 mutation with survival of immune checkpoint inhibitor in patients with cancer
MUC16 mutation has been shown to be associated with survival outcomes in cancers, but the association of MUC16 mutation with clinical outcomes of immunotherapy remains to be explored. Here we performed clinical validation of MUC16 mutation as a predictive biomarker of immune checkpoint inhibitor (ICI) in patients with cancer. This study analyzed genomic data from the cBioPortal database. Nonsynonymous mutations of MUC16 were considered. Kaplan-Meier survival analysis and logistic regression models were applied. Primary outcomes were overall survival (OS) and progression free survival (PFS). A total of 2,129 cancer patients treated with ICI were included. The tumor mutation burden of patients with MUC16 mutations was substantially higher than in those without the mutations (Wilcoxon rank sum test, P < 0.0001). Patients with MUC16 mutations were associated with better OS benefits from ICI in non–small cell lung cancer (NSCLC) (hazard ratio [HR] 0.38, 95% CI 0.17 to 0.86) and in pancancer (HR 0.79, 95% CI 0.65 to 0.96) compared with wild-type population. Similar findings were observed in terms of PFS in NSCLC (HR 0.70, 95% CI 0.57 to 0.87) and in pancancer (HR 0.42, 95% CI 0.28 to 0.64). We demonstrated that MUC16 mutation can predict survival benefit from ICI therapy in cancer, and suggested that MUC16 mutation should be integrated into predictive biomarker panels for ICI therapy and be validated in future prospective clinical trials. Herui Yao. Grants from the National Natural Science Foundation of China (81372819, 81572596, U1601223), the Natural Science Foundation of Guangdong Province (2017A030313828), the Guangzhou Science and Technology Program (201704020131), the Sun Yat-Sen University Clinical Research 5010 Program (2018007). All authors have declared no conflicts of interest.
- 15 December 2019
- Published by Elsevier in Annals of Oncology
- Vol. 30 (Supplement) , xi51-xi52
Association of MUC16 mutation with survival of immune checkpoint inhibitor in patients with cancer
MUC16 mutation has been shown to be associated with survival outcomes in cancers, but the association of MUC16 mutation with clinical outcomes of immunotherapy remains to be explored. Here we performed clinical validation of MUC16 mutation as a predictive biomarker of immune checkpoint inhibitor (ICI) in patients with cancer. This study analyzed genomic data from the cBioPortal database. Nonsynonymous mutations of MUC16 were considered. Kaplan-Meier survival analysis and logistic regression models were applied. Primary outcomes were overall survival (OS) and progression free survival (PFS). A total of 2,129 cancer patients treated with ICI were included. The tumor mutation burden of patients with MUC16 mutations was substantially higher than in those without the mutations (Wilcoxon rank sum test, P < 0.0001). Patients with MUC16 mutations were associated with better OS benefits from ICI in non–small cell lung cancer (NSCLC) (hazard ratio [HR] 0.38, 95% CI 0.17 to 0.86) and in pancancer (HR 0.79, 95% CI 0.65 to 0.96) compared with wild-type population. Similar findings were observed in terms of PFS in NSCLC (HR 0.70, 95% CI 0.57 to 0.87) and in pancancer (HR 0.42, 95% CI 0.28 to 0.64). We demonstrated that MUC16 mutation can predict survival benefit from ICI therapy in cancer, and suggested that MUC16 mutation should be integrated into predictive biomarker panels for ICI therapy and be validated in future prospective clinical trials. Herui Yao. Grants from the National Natural Science Foundation of China (81372819, 81572596, U1601223), the Natural Science Foundation of Guangdong Province (2017A030313828), the Guangzhou Science and Technology Program (201704020131), the Sun Yat-Sen University Clinical Research 5010 Program (2018007). All authors have declared no conflicts of interest.